- Home
- JZXN vs SNGX Comparison
JZXN vs SNGX Comparison
Compare JZXN & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JZXN
- SNGX
- Stock Information
- Founded
- JZXN 2017
- SNGX 1987
- Country
- JZXN China
- SNGX United States
- Employees
- JZXN N/A
- SNGX N/A
- Industry
- JZXN Retail-Auto Dealers and Gas Stations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- JZXN Consumer Discretionary
- SNGX Health Care
- Exchange
- JZXN Nasdaq
- SNGX Nasdaq
- Market Cap
- JZXN 10.7M
- SNGX 9.6M
- IPO Year
- JZXN 2021
- SNGX 1987
- Fundamental
- Price
- JZXN $1.46
- SNGX $3.16
- Analyst Decision
- JZXN
- SNGX
- Analyst Count
- JZXN 0
- SNGX 0
- Target Price
- JZXN N/A
- SNGX N/A
- AVG Volume (30 Days)
- JZXN 718.8K
- SNGX 46.1K
- Earning Date
- JZXN 12-27-2024
- SNGX 11-08-2024
- Dividend Yield
- JZXN N/A
- SNGX N/A
- EPS Growth
- JZXN N/A
- SNGX N/A
- EPS
- JZXN N/A
- SNGX N/A
- Revenue
- JZXN $7,597,423.00
- SNGX $364,183.00
- Revenue This Year
- JZXN N/A
- SNGX N/A
- Revenue Next Year
- JZXN N/A
- SNGX $76.64
- P/E Ratio
- JZXN N/A
- SNGX N/A
- Revenue Growth
- JZXN 81.94
- SNGX N/A
- 52 Week Low
- JZXN $1.00
- SNGX $1.83
- 52 Week High
- JZXN $67.60
- SNGX $19.20
- Technical
- Relative Strength Index (RSI)
- JZXN 50.06
- SNGX 41.70
- Support Level
- JZXN $1.50
- SNGX $2.93
- Resistance Level
- JZXN $2.25
- SNGX $3.35
- Average True Range (ATR)
- JZXN 0.35
- SNGX 0.19
- MACD
- JZXN 0.02
- SNGX -0.01
- Stochastic Oscillator
- JZXN 35.77
- SNGX 37.10
About JZXN Jiuzi Holdings Inc.
Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its business segments are sales of NEVs and Franchisees services. The company generates a majority of its revenue from the NEVs segment. Geographically, the firm operates in China.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).